Praxis Precision Medicines, Inc.
$340.84
0%
2026-04-22 10:12:13
praxismedicines.com
NMS: PRAX
Explore Praxis Precision Medicines, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.47 B
Current Price
$340.84
52W High / Low
$356 / $28.79
Stock P/E
—
Book Value
$34.85
Dividend Yield
—
ROCE
-37.15%
ROE
-45.83%
Face Value
—
EPS
$-13.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
168
Beta
2.97
Debt / Equity
0.01
Current Ratio
10.22
Quick Ratio
10.22
Forward P/E
-36.57
Price / Sales
—
Enterprise Value
$8.21 B
EV / EBITDA
-25.17
EV / Revenue
—
Rating
Strong Buy
Target Price
$629.24
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Citius Pharmaceuticals, Inc. | $0.87 | — | $19.56 M | — | -44.79% | -47.85% | $2.48 / $0.63 | $3.57 |
| 2. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 3. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 4. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 5. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 6. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 7. | Crinetics Pharmaceuticals, Inc. | $40.25 | — | $4.21 B | — | -49.63% | -40.17% | $57.99 / $25.83 | $10.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 7.46 M |
| Operating Profit | -97.04 M | -78.36 M | -76.07 M | -74.73 M | -63.96 M |
| Net Profit | -88.91 M | -73.93 M | -71.13 M | -69.3 M | -58.68 M |
| EPS in Rs | -3.19 | -2.65 | -2.55 | -2.49 | -2.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 8.55 M | 2.45 M | 0 M |
| Operating Profit | -326.2 M | -200.16 M | -126.37 M | -214.99 M |
| Net Profit | -303.27 M | -182.82 M | -123.28 M | -214.03 M |
| EPS in Rs | -10.89 | -6.56 | -4.43 | -7.68 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 937.91 M | 483.11 M | 87.95 M | 115.13 M |
| Total Liabilities | 59.77 M | 37.66 M | 18.28 M | 39.02 M |
| Equity | 878.14 M | 445.45 M | 69.67 M | 76.11 M |
| Current Assets | 610.91 M | 404.37 M | 84.88 M | 110.84 M |
| Current Liabilities | 59.77 M | 37.55 M | 15.75 M | 34.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -249.07 M | -131.76 M | -111.14 M | -185.04 M |
| Investing CF | -311.15 M | -248.49 M | 38.95 M | 96.89 M |
| Financing CF | 702.17 M | 514.32 M | 91.87 M | 10.46 M |
| Free CF | -249.12 M | -131.76 M | -111.19 M | -185.49 M |
| Capex | -0.06 M | — | -0.05 M | -0.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 249.53% | — | — | — |
| Earnings Growth % | -48.3% | 42.4% | — | — |
| Profit Margin % | -2137.48% | -5037.88% | — | — |
| Operating Margin % | -2340.29% | -5164.41% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -2336.1% | -5146.75% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-11-29 | 1:0.0666667 |